Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Cytox Announces Participation in INSIGHT Alzheimer's Study
October 13, 2015
Oxford, United Kingdom - Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has confirmed its participation in the pioneering French INSIGHT study of Alzheimers disease (AD). The Cytox proposal, SNP Profiling as an Approach to Risk Stratification for Future Cognitive Decline in Elderly Subjective Memory Complainers, has been reviewed and approved by the INSIGHT Scientific Committee.
INSIGHT is a study of Alzheimers disease and one of the first in the world to monitor healthy subjects at risk. Led by Professor Harald Hampel, AXA-UPMC Chair at Université Pierre et Marie Curie, Paris, France and Professor Bruno Dubois, Director of IM2A (Institute of Memory and Alzheimers Disease, located at La Pitié Salpêtrière University Hospital in Paris), and based at the ICM (Brain and Spine Institute, Paris), the study is a collaboration with Pfizer and Avid. The project involves monitoring 350 healthy volunteer subjects aged 70-85 years, with normal memory function that are stratified in a group that is amyloid-positive and a control group that is negative as defined by PET. Its objective is not to detect or treat disease, but to observe changes in these healthy subjects eventually progressing to first clinical symptoms related to Alzheimers disease. The seven-year study is being conducted at the IM2A and ICM. INSIGHT is an ancillary study of the French MEMENTO national cohort.
This affords Cytox an excellent opportunity to generate initial cross-sectional data according to Dr. Richard Pither, CEO of Cytox, All of these subjects in Paris have been assessed in an internationally unique mono-centre setting using an extensive range of standardized methods, clinical and biomarkers, allowing us to compare our SNP genotyping results with biomarker status, including CSF and PET-amyloid imaging, and then, in time, longitudinal data as these subjects are followed up in coming years. These samples are likely to represent a good proportion of our first genotyping analysis using the Cytox-Affymetrix genoTOR MKI Research array.
Cytox Limited is a UK-based company with a unique scientific and proprietary technology platform, working in partnership with Affymetrix. Through the application of this fundamental science and our specific know-how, we are elucidating the biology and genetics behind dementia, as well as developing prognostic tests for cognitive decline and individual risk of developing Alzheimers disease or other dementias.
INSIGHT is a unique study aimed at better understanding the factors that induce Alzheimers disease. The study is being carried out by teams at the IM2A (Institute of Memory and Alzheimer Disease, Paris) and the ICM (Brain and Spine Institute, Paris), associated in the IHU-A-ICM (Paris Institute of Translational Neuroscience), and in collaboration with Pfizer and Avid. The objective of the study is to follow 350 healthy volunteers, aged 70 to 85 years, who suffer from memory problems but dont yet have Alzheimer disease, with different techniques such as PET imaging of amyloid because of their risk, in order to understand the natural history of Alzheimer disease.
INSIGHT is made possible through an innovative new scheme in medical research, a multi-partner foundation that focuses the Investissements dAvenir (Investment for the Future) programme via IHU-A-ICM and Pfizer, together with the teams at IM2A and ICM, on the shared objective of better understanding Alzheimers disease. www.icm-institute.org/en/alzheimer-en
Memento is a national cohort funded by the Fondation Plan Alzheimer and sponsored by the Bordeaux University Hospital (CHU Bordeaux). This cohort aims at studying the evolution of a variety of potentially early signs (cognitive complaints, deficit in some domain of cognition, psycho-behavioural disturbances, changes in imaging or biological markers) of Alzheimers disease and related dementia and to estimate the prognostic value of different markers (neuro-psychological, vascular, psychopathological, socio-educational, genetic, biological, neuro-imaging) on the progression to clinical dementia or severe cognitive deterioration stages, and then to death.